Pan-cancer analysis of the extent and consequences of intratumor heterogeneity

Nature Medicine

Volumn 22, Issue 1, 2016, Pages 105-113

  Andor, Noemi ^a,b   Graham, Trevor A ^c   Jansen, Marnix ^c   Xia, Li C ^a   Aktipis, C Athena ^d,e   Petritsch, Claudia ^d,f   Ji, Hanlee P ^a,e   Maley, Carlo C ^d,e,g  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ARIZONA STATE UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; PROTEIN TYROSINE KINASE; TENOFOVIR 3 HEXADECYLOXYPROPYL ESTER;

ALGORITHM; ARTICLE; BIOINFORMATICS; BLADDER CANCER; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; COPY NUMBER VARIATION; EXOME; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; GENOME ANALYSIS; GENOMIC INSTABILITY; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HEALTH CARE COST; HUMAN; INTRATUMOR HETEROGENEITY; KIDNEY CARCINOMA; MOLECULAR CLONING; NEOPLASM; PLOIDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TUMOR DIFFERENTIATION; BIOLOGY; CELL CLONE; GENETICS; MORTALITY; MUTATION; NUCLEAR SHAPE; PROPORTIONAL HAZARDS MODEL;

CELL NUCLEUS SHAPE; CLONE CELLS; COMPUTATIONAL BIOLOGY; DNA COPY NUMBER VARIATIONS; GENE FREQUENCY; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; HUMANS; MUTATION; NEOPLASMS; PROPORTIONAL HAZARDS MODELS;

EID: 84954242823     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3984     Document Type: Article

References (54)

1. Marusyk, A., Polyak, K. Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 1805, 105-117 (2010).
2. Bonavia, R., Inda, M.-M., Cavenee, W.K., Furnari, F.B. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 71, 4055-4060 (2011).
3. Wang, Y. et al. Clonal evolution in breast cancer revealed by single-nucleus genome sequencing. Nature 512, 155-160 (2014).
4. Nowell, P.C. The clonal evolution of tumor cell populations. Science 194, 23-28 (1976).
5. Greaves, M., Maley, C.C. Clonal evolution in cancer. Nature 481, 306-313 (2012).
6. McGranahan, N. et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med. 7, 283ra54 (2015).
7. Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994-1007 (2012).
8. Landau, D.A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 (2013).
9. Mroz, E.A., Tward, A.D., Hammon, R.J., Ren, Y., Rocco, J.W. Intratumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from the Cancer Genome Atlas. PLoS Med. 12, e1001786 (2015).
10. Zack, T.I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134-1140 (2013).
11. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013).
12. Ciriello, G. et al. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127-1133 (2013).
13. Almendro, V. et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep. 6, 514-527 (2014).
14. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
15. Oesper, L., Satas, G., Raphael, B.J. Quantifying tumor heterogeneity in whole-genome and whole-exome sequencing data. Bioinformatics 30, 3532-3540 (2014).
16. Li, B., Li, J.Z. A general framework for analyzing tumor subclonality using SNP array and DNA sequencing data. Genome Biol. 15, 473 (2014).
17. Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396-398 (2014).
18. Andor, N., Harness, J.V., Müller, S., Mewes, H.W., Petritsch, C. EXPANDS: expanding ploidy and allele frequency on nested subpopulations. Bioinformatics 30, 50-60 (2014).
19. Ha, G. et al. TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. Genome Res. 24, 1881-1893 (2014).
20. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
21. Sathirapongsasuti, J.F. et al. Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics 27, 2648-2654 (2011).
22. Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
23. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
24. Barber, L.J., Davies, M.N., Gerlinger, M. Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. Curr. Opin. Genet. Dev. 30, 1-6 (2015).
25. Yadav, V.K., De, S. An assessment of computational methods for estimating purity and clonality using genomic data derived from heterogeneous tumor tissue samples. Brief. Bioinform. 16, 232-241 (2015).
26. Yoshihara, K. et al. Inferring tumor purity, and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).
27. Tajiri, R. et al. Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization. Hum. Pathol. 45, 725-734.
28. Sakurada, A., Lara-Guerra, H., Liu, N., Shepherd, F.A., Tsao, M.-S. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J. Thorac. Oncol. 3, 527-529 (2008).
29. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012).
30. Vitale, M. Intratumor BRAFV600E heterogeneity and kinase inhibitors in the treatment of thyroid cancer: a call for participation. Thyroid 23, 517-519 (2013).
31. Carpenter, A.E. et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 7, R100 (2006).
32. Wang, W., Ozolek, J.A., Rohde, G.K. Detection and classification of thyroid follicular lesions based on nuclear structure from histopathology images. Cytometry A 77, 485-494 (2010).
33. Hartwell, K.A. et al. Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat. Chem. Biol. 9, 840-848 (2013).
34. Yamamoto, S. et al. Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens. Breast Cancer 20, 262-270 (2013).
35. Cazier, J.-B. et al. Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. Nat. Commun. 5, 3756 (2014).
36. Swanton, C. Cancer evolution constrained by mutation order. N. Engl. J. Med. 372, 661-663 (2015).
37. Cancer Genome Atlas Research Network. et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481-2498 (2015).
38. Roylance, R. et al. Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol. Biomarkers Prev. 20, 2183-2194 (2011).
39. Birkbak, N.J. et al. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res. 71, 3447-3452 (2011).
40. Bochtler, T. et al. Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. J. Clin. Oncol. 31, 3898-3905 (2013).
41. Merlo, L.M.F. et al. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev. Res. (Phila.) 3, 1388-1397 (2010).
42. Maley, C.C. et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38, 468-473 (2006).
43. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
44. Roth, A. et al. JointSNVMix: a probabilistic model for accurate detection of somatic mutations in normal-tumor-paired next-generation sequencing data. Bioinformatics 28, 907-913 (2012).
45. Sathirapongsasuti, J.F. et al. Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics 27, 2648-2654 (2011).
46. Andor, N., Harness, J.V., Müller, S., Mewes, H.W., Petritsch, C. EXPANDS: expanding ploidy and allele frequency on nested subpopulations. Bioinformatics 30, 50-60 (2014).
47. Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396-398 (2014).
48. Goode, A., Gilbert, B., Harkes, J., Jukic, D., Satyanarayanan, M. OpenSlide: a vendor-neutral software foundation for digital pathology. J. Pathol. Inform. 4, 27 (2013).
49. Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 46, 310-315 (2014).
50. Huang, D.W., Sherman, B.T., Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).
51. Huang, D.W., Sherman, B.T., Lempicki, R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1-13 (2009).
52. Griffith, M. et al. DGIdb: mining the druggable genome. Nat. Methods 10, 1209-1210 (2013).
53. Swanton, C. Cancer evolution constrained by mutation order. N. Engl. J. Med. 372, 661-663 (2015).
54. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013).